Pharma
Stay updated with the latest happenings in the pharmaceutical industry. Get insights into drug development, innovations, regulatory updates, and emerging trends. Discover the advancements shaping the future of healthcare. Explore the world of pharma with our comprehensive coverage at Pharmtales.com.
Anthosâ ABP-959 outperforms Xarelto in preventing bleeding events in phase 2 trial
Blackstone Life Sciences’ substantial $250 million investment in an ex-Novartis drug candidate has yielded yet another positive outcome in its ...
Nobel Prize Winner in Chemistry Joins Acepodia to Develop Novel Cell Therapies for Cancer
Renowned Nobel laureate Carolyn Bertozzi, Ph.D., has joined Acepodia as its Chief Scientific Adviser, marking a significant development in the ...
Novartis commissions art exhibition to raise awareness of rare blood cancers
Novartis has taken a creative approach to raise awareness about rare blood cancers, specifically myeloproliferative neoplasms (MPNs), which impact approximately ...
Enhertu, a Breakthrough Therapy for HER2 Mutant NSCLC, Gets EU Nod
Enhertu (trastuzumab deruxtecan) has received a positive recommendation for approval in the European Union (EU) as a standalone treatment for ...
Quizartinib Gets Green Light in EU for Treating Acute Myeloid Leukemia
Daiichi Sankyo has received a positive recommendation for the approval of quizartinib in the European Union (EU). This recommendation is ...
Lyndra Therapeutics slashes staff and moves HQ ahead of pivotal data for weekly oral schizophrenia pill
Lyndra Therapeutics is undergoing significant changes, including the appointment of Jessica Ballinger as its new CEO, following the replacement of ...
FDA Approves Temodar (Temozolomide) Label Updates for Anaplastic Astrocytoma Treatment
In a significant development, the FDA has granted approval for temozolomide (marketed as Temodar) to be used as adjuvant therapy ...
FDA Approves Ojjaara (Momelotinib) for Treating High-Risk Myelofibrosis with Anemia a new competitor of Jakafi
The FDA has granted approval for momelotinib, marketed as Ojjaara, as a groundbreaking treatment option for adult patients grappling with ...
Bristol Myers Squibb aims for 25+ new indications to overcome patent losses and pricing challenges
Bristol Myers Squibb is placing a significant bet on its robust pipeline to weather challenges such as the Inflation Reduction ...
Mayo Clinic and GE Healthcare team up to advance theranostic imaging for cancer
The Mayo Clinic is strengthening its longstanding partnership with GE Healthcare by embarking on a series of new joint research ...
FDA approves Beacon Biosignalsâ headset that uses AI to monitor and improve sleep quality
Beacon Biosignals has achieved an impressive milestone shortly after acquiring EEG headset manufacturer Dreem. The company has received FDA clearance ...
Johnson & Johnson and GSK sued for false advertising of decongestant products
A class-action lawsuit has been filed against pharmaceutical giants Johnson & Johnson and Procter & Gamble in a US federal ...
PTC Therapeuticsâ Translarna at risk of losing EU approval after failing to impress FDA for DMD
PTC Therapeutics is facing a significant setback as it seeks to maintain approval for its Duchenne muscular dystrophy (DMD) therapy, ...
Bayerâs new CEO plans to slash management jobs as part of a major restructuring: Reuters
Bill Anderson, Bayer’s relatively new CEO, is reportedly gearing up to make substantial changes within the pharmaceutical giant, starting with ...
MDMA shows promise for PTSD treatment in second phase 3 trial, paving way for FDA approval
MAPS Public Benefit Corporation has recently unveiled phase 3 data, marking a significant milestone in its quest for FDA approval ...
Iovanceâs cell therapy for skin cancer faces three-year delay due to FDA issues
The FDA has introduced a new twist in the ongoing Iovance Biotherapeutics saga, causing further delays in the approval process ...
RayzeBio and Neumora raise over $500M combined in successful IPOs for cancer therapies
Closing the week on an optimistic note, two biotech IPOs have successfully crossed the finish line with impressive results. RayzeBio, ...
Clinigen launches initiative to bridge the gap between rare disease communities and pharma
Clinigen, a pharmaceutical services company based in the UK, is launching the NaviGATE initiative to empower patient advocacy groups within ...
Johnson & Johnson rebrands itself with a new logo and slogan
First Sanofi, GSK, and now Johnson & Johnson are all undergoing significant rebranding efforts in the pharmaceutical industry. In a ...
How Tezspire helps a punk rocker with severe asthma live his life to the fullest
Amgen and AstraZeneca are making a triumphant return to television advertising to highlight how Tezspire is transforming the lives of ...
Alexion settles Soliris sales practices lawsuit for $125 million
After nearly seven years since the departure of Alexion’s CEO and CFO amidst an investigation into improper sales practices, the ...
Almirall uses famous paintings to raise awareness of atopic dermatitis
Almirall, a Barcelona-based pharmaceutical company collaborated with Eli Lilly on the development of the atopic dermatitis drug candidate lebrikizumab, has ...
FDA approves worldâs first MRI-compatible breast biopsy robot
Insight Medbotics has achieved FDA clearance for what it claims to be the world’s first surgical robot designed to operate ...
Moderna axes four programs, including two former AstraZeneca collaborations
Moderna, following its recent phase 3 success with an mRNA flu vaccine, has made the decision to remove four clinical ...
Cerba HealthCare buys Cirion Biopharma to boost bioanalytical services
French clinical trial lab and diagnostics provider Cerba HealthCare has acquired Canadian CRO Cirion Biopharma in a move aimed at ...
FDA panel backs Alnylamâs Onpattro for rare heart condition despite small benefit
After facing doubts from the FDA regarding the expansion of its RNA-silencing drug Onpattro into the treatment of transthyretin amyloidosis ...
Pfizerâs Nurtec gets thumbs up from NICE for migraine attacks
England’s National Institute of Care and Health Excellence (NICE) has granted approval for Pfizer’s Vydura (rimegepant) as a treatment for ...
J&J rebrands Janssen and medtech segments after Kenvue spinoff
Johnson & Johnson (J&J) has undergone a significant corporate transformation, unveiling a new logo and announcing substantial changes to its ...
AbbVie drops option on Harpoonâs BCMA TriTAC for multiple myeloma
AbbVie has decided against pursuing its option on Harpoon Therapeutics’ anti-BCMA T-cell engager HPN217, thus avoiding a $200 million payment ...
Akili slashes 40% of staff, shifts to OTC sales for digital therapies
In response to the challenges faced by prescription digital therapeutics companies, Akili is taking a new approach to navigate the ...
